2011 Scrip 100: GSK goes back to return on investment

Flagging investor confidence in the traditional pharmaceutical model in the years following its mega-merger convinced GlaxoSmithKline that it needed to execute drastic change. Brought into the corporate team to help make it happen, chief strategy officer David Redfern tells Elizabeth Sukkar how a more aggressive approach has refocused GSK on R&D metrics that deliver true value.